Pleural Diseases Market Report 2026

The pleural diseases market size has grown strongly in recent years. It will grow from $5.21 billion in 2025 to $5.6 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing incidence of respiratory diseases, rising prevalence of pleural effusion and mesothelioma, wider availability of diagnostic imaging, expansion of pulmonology services, growth in hospital-based respiratory care.

The pleural diseases market size is expected to see strong growth in the next few years. It will grow to $7.35 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to increasing investments in early cancer detection, rising demand for minimally invasive diagnostics, expansion of precision medicine approaches, growing focus on outpatient respiratory care, advancements in pleural disease therapeutics. Major trends in the forecast period include increasing adoption of advanced imaging diagnostics, rising use of minimally invasive pleural interventions, growing integration of molecular diagnostic tools, expansion of early disease detection programs, enhanced focus on personalized treatment approaches.

The growing prevalence of infectious diseases is expected to drive the growth of the pleural diseases market going forward. Infectious diseases are conditions caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites. Changes in human behavior, environmental factors, and increased global travel have contributed to the rising incidence of infectious diseases. Conditions such as bacterial pneumonia, tuberculosis, and viral infections can lead to pleural diseases by causing inflammation, infection, or fluid buildup in the pleural cavity. For instance, in January 2023, according to the National Library of Medicine, a US based medical research and information library, infectious diseases account for more than 52 million deaths each year, placing nearly half of the world’s population at risk. Additionally, around 14 million children under the age of five die annually, with approximately 70% of these deaths linked to diseases that could be prevented through vaccination. Therefore, the increasing prevalence of infectious diseases is contributing to the growth of the pleural diseases market.

Major companies operating in the pleural diseases market are concentrating on the development of innovative treatment options, including ready to use injectable therapies, to enhance convenience, shorten preparation time, and reduce the risk of dosing errors. Ready to use injectable treatments are pre formulated and pre diluted medications that do not require mixing or reconstitution before administration, ensuring accuracy and ease of use. For instance, in April 2024, Amneal Pharmaceuticals, a US based pharmaceutical company, introduced PEMRYDI RTU, the first ready to use formulation of pemetrexed for injection. This product supports patients with pleural diseases by offering a convenient treatment option that eliminates the need for preparation, reduces administration time, lowers the likelihood of dosing errors, and improves access to effective therapies for conditions such as malignant pleural mesothelioma.

In October 2023, Aileron Therapeutics Inc., a US based biopharmaceutical company, acquired Lung Therapeutics Inc. for an undisclosed amount. This acquisition enhances Aileron’s development pipeline by incorporating LTI 03 for idiopathic pulmonary fibrosis and LTI 01 for loculated pleural effusions, thereby expanding its focus on orphan pulmonary and fibrosis related diseases. Lung Therapeutics Inc. is a US based biopharmaceutical company focused on developing innovative peptide based therapies for fibrosis and rare pulmonary disorders.

Major companies operating in the pleural diseases market are Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb Company, GSK plc, Astrazeneca plc, Koninklijke Philips N.V., Becton Dickinson and Company, Boehringer Ingelheim International GmbH, Sanofi SA, Penn Medicine, Henry Ford Health, Dragerwerk AG, Emory Healthcare, Boston Medical Center, Cook Medical, WakeMed, Weill Cornell Medicine, Fox Chase Cancer Center, B. Braun SE, Bicakcilar, Redax S.p.a, Rocket Medical.

North America was the largest region in the pleural diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pleural diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pleural diseases market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the pleural diseases market by increasing costs of imported diagnostic imaging equipment, thoracoscopic instruments, molecular testing kits, and minimally invasive surgical tools. Hospitals and diagnostic centers in North America and Europe are most affected due to dependence on imported medical technologies, while Asia-Pacific faces increased costs for advanced diagnostic imports. These tariffs are raising diagnostic and treatment expenses. However, they are also encouraging domestic production of diagnostic devices, regional manufacturing of medical instruments, and localized innovation in pleural disease management solutions.

The pleural diseases market research report is one of a series of new reports that provides pleural diseases market statistics, including pleural diseases industry global market size, regional shares, competitors with a pleural diseases market share, detailed pleural diseases market segments, market trends and opportunities, and any further data you may need to thrive in the pleural diseases industry. This pleural diseases market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pleural diseases are a group of medical conditions that affect the pleura, the double layered membrane that surrounds the lungs. These conditions may involve inflammation, infection, or other pathological changes of the pleura. Pleural diseases often cause symptoms such as chest pain, shortness of breath, coughing, and breathing difficulty, and they are commonly diagnosed using imaging tests including chest X rays or CT scans.

The primary disease types within pleural diseases include pleurisy, pleural effusion, pneumothorax, mesothelioma, and others. Pleurisy is marked by inflammation of the pleura and leads to sharp chest pain, often associated with infections or autoimmune disorders. Treatment approaches include medications, thoracentesis, pleurodesis, minimally invasive procedures, and surgical interventions. Diagnostic methods involve imaging techniques, molecular diagnostics, thoracoscopy, and pleuroscopy. These services are used across hospitals, clinics, diagnostic centers, and research or academic institutions.

The pleural diseases market consist of revenues earned by entities by providing services such as diagnostic, pleurodesis, respiratory therapy, rehabilitation, and biopsy procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The pleural diseases market also includes sales of antibiotics, chemotherapeutic agents, thoracentesis kits, chest tubes and drainage systems, and pleural biopsy needles. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.